Dr. Chengcang Charles Wu, founder and CEO of Intact Genomics, has been named 2017 “Inventor of the Year” by The Bar Association of Metropolitan St. Louis. For more information, please read the press release “Inventor of the Year rewarded to St. Louis business owner” from St. Louis Post-Dispatch.
Intact Genomics was selected as one Nominee of the Diagnostics & Beyond category in the Buzz of BIO Contest, recognizing the most innovative companies at the 2017 BIO Investor Forum. For more information, please go to: http://bit.ly/IamTheBuzz.
BIO (Biotechnology Innovation Organization) is the world’s largest biotechnology trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The 2017 BIO Investor Forum was hosted in San Francisco, California in October 17-18.
Nature Chemical Biology published NIH SBIR supported research by scientists from Intact Genomics, UW-Madison and Northwestern University.
The August issue of Nature Chemical Biology (August 2017, Vol 13, No 8) published NIH SBIR supported research – “A scalable platform to identify fungal secondary metabolites and their gene clusters” by scientists from Intact Genomics, UW-Madison and Northwestern University. The cover page of that issue was an illustration of the Fungal Artificial Chromosomes (FAC) platform, which highlights the novelty and significance of FAC technology for the discovery of fungal natural products and potential drugs leads. For more details, click http://www.nature.com/nchembio/journal/v13/n8/covers/index.html.
The cover depicts conidiophores of the fungus Aspergillus nidulans carrying a fungal artificial chromosome (FAC), imaged by a scanning electron microscope and colored artificially. Filamentous fungi are prolific producers of secondary metabolites, and the combination of FAC technology with metabolomic scoring enables the high-throughput linkage of these metabolites with their biosynthetic gene clusters.
Intact has partnered with Geneva Biotech to offer North American customers competent cells containing Geneva Biotech’s viral genomes. Geneva Biotech is a privately held biotechnology company based in Geneva, Switzerland. Geneva Biotech develops a world class portfolio of viral and nonviral gene delivery systems and to market them across a broad spectrum of application fields, for more information about Geneva Biotech, click: http://geneva-biotech.com. Intact Genomics is proud to partner with Geneva Biotech to manufacture and distribute MultiBac™ and MultiBacMam™ Cell Lines and Kits.
Scientists from Intact Genomics, University of Wisconsin – Madison and Northwestern University, Partnered to Build New Platform for the Discovery of New Drug Leads from the Microbial World
St. Louis – (June 12, 2017) Today scientists from St. Louis-based Intact Genomics, a world leader of research and services around large DNA fragment cloning and metagenomics related technologies; the University of Wisconsin – Madison; and Northwestern University, announced that their research to develop a new, scalable platform that harvests valuable lead compounds from fungi, using a technology known as Fungal Artificial Chromosomes with Metabolomic Scoring (FAC-MS) was published by the Nature Chemical Biology. For the article please click here.
The FAC-MS approach harnesses fungi to create powerful molecules honed through evolution by capturing large swaths of their DNA in a special system for robust production and identification of new molecules. Most notable, the company has also developed another disruptive technology of soil shuttle BAC-NGS (next generation sequencing) to capture 100-kb large DNA directly from soil and environmental uncultivable microbes for large-scale natural product discovery. The new 100-kb large DNA platforms will transform the process of discovering new bioactive molecules for application to numerous human diseases through the systematic discovery of new drug leads from the microbial world. For more information, please click here.
There are more press releases: “Fungal Genomic Breakthrough Unlocks a ‘Gold Rush’ of New Drug Discoveries” from Discovery Channel Seeker; “Intact Genomics, Collaborators Develop Workflow for Natural Products Discovery” from Genomeweb; and “Technology unlocks mold genomes for new drugs” from Phys.org.
CEO of Intact Genomics is invited to speak at Synthetic Biology for Natural Products Conference in Cancun, Mexico
Dr. Chengcang Charles Wu, CEO of Intact Genomics is an invited speaker to present: “Access 1,000,000 Full-Length secondary Metabolite Biosynthetic Gene Clusters and Their Natural Product Compounds from Microbes and Metagenomes” at Synthetic Biology for Natural Products Conference in Cancun, Mexico, March 5-March 8, 2017.
Intact Genomics presented at Advances in Genome Biology and Technology General Meeting (AGBT) 2017 in Florida, USA
Intact Genomics presented a Poster presentation of ‘Single Molecule Sequencing of 100 to 200 kb DNA Fragments to Rapidly and Cost-Effectively Assemble de novo Arthropod Genomes’ at the 2017 Advances in Genome Biology and Technology General Meeting (AGBT) from February 13-16, 2017 in Hollywood, Florida.
Intact Genomics CEO, Dr. Chengcang Charles Wu was invited to speak about FAC technology at Functional Metagenomics 2016 in Inderøy, Norway, September 25-28, 2016.
On August 29, 2016, The Centers for Disease Control and Prevention/ National Center for Emerging and Zoonotic Infectious Diseases awarded Intact Genomics a Small Business Innovation Research (SBIR) Phase I contract grant. The intent of this study is to develop the techniques and enzyme reagents for 100kb single molecule sequencing with an existing sequence platform and to enable gold-standard genomic assembly of all pathogen-vector arthropod large/complex genomes with low cost.
On July 12, 2016, The National Institute of Health awarded Intact Genomics a Small Business Innovation Research (SBIR) second Phase II grant to further develop the patent-pending fungal artificial chromosome (FAC) technology. The new study’s intent is to activate silent and cryptic fungal biosynthetic gene clusters for natural product discovery by a superior ‘FAC recombineering and transgenic animal-like’ system in Aspergillus nidulans.